Abstract
In industrialized countries, Alzheimer's disease represents the most devastating neurodegenerative disorder in elderly people and the search for a disease modifying agent is still justified by this unmet need. Several possible targets have been explored to find an appropriate drug therapy, and in this review, dual inhibitors of beta secretase and glycogen synthase kinase 3, recently reported in literature, will be appraised. Applying a ligand-based approach, the triazinone core emerged as a suitable scaffold to simultaneously bind the aspartic dyad of BACE-1 and the ATP site of GSK-3β, leading to a series of small molecules endowed with a balanced micromolar affinity and a promising pharmacokinetic profile.
Differently, by means of a structure-based approach, a series of well-balanced dual binding molecules were designed, taking advantage of the versatility of the curcumin scaffold. For some of these new compounds a potential neuroprotective effect was also observed, due to their ability to counteract the oxidative stress through the inhibition of NQO1 enzyme.
Finally, different virtual screening analyses were performed, leading to the identification of new potential scaffolds deserving further development.
Keywords: Dual BACE-1/GSK-3β, Alzheimer, Neurodegenerative Diseases (ND), Precursor protein, Neurofibrillary tangles (NFTs), NQO1 enzyme.
Current Topics in Medicinal Chemistry
Title:Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review
Volume: 17 Issue: 31
Author(s): Angela Rampa*, Silvia Gobbi, Rita Maria Concetta Di Martino, Federica Belluti and Alessandra Bisi*
Affiliation:
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, I-40126 Bologna,Italy
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, Via Belmeloro 6, I-40126 Bologna,Italy
Keywords: Dual BACE-1/GSK-3β, Alzheimer, Neurodegenerative Diseases (ND), Precursor protein, Neurofibrillary tangles (NFTs), NQO1 enzyme.
Abstract: In industrialized countries, Alzheimer's disease represents the most devastating neurodegenerative disorder in elderly people and the search for a disease modifying agent is still justified by this unmet need. Several possible targets have been explored to find an appropriate drug therapy, and in this review, dual inhibitors of beta secretase and glycogen synthase kinase 3, recently reported in literature, will be appraised. Applying a ligand-based approach, the triazinone core emerged as a suitable scaffold to simultaneously bind the aspartic dyad of BACE-1 and the ATP site of GSK-3β, leading to a series of small molecules endowed with a balanced micromolar affinity and a promising pharmacokinetic profile.
Differently, by means of a structure-based approach, a series of well-balanced dual binding molecules were designed, taking advantage of the versatility of the curcumin scaffold. For some of these new compounds a potential neuroprotective effect was also observed, due to their ability to counteract the oxidative stress through the inhibition of NQO1 enzyme.
Finally, different virtual screening analyses were performed, leading to the identification of new potential scaffolds deserving further development.
Export Options
About this article
Cite this article as:
Rampa Angela*, Gobbi Silvia, Concetta Di Martino Maria Rita, Belluti Federica and Bisi Alessandra*, Dual BACE-1/GSK-3β Inhibitors to Combat Alzheimer's Disease: A Focused Review, Current Topics in Medicinal Chemistry 2017; 17 (31) . https://dx.doi.org/10.2174/1568026618666180112161406
DOI https://dx.doi.org/10.2174/1568026618666180112161406 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sirtuin3 in Neurological Disorders
Current Drug Research Reviews Pin1: A New Genetic Link between Alzheimer’s Disease, Cancer and Aging
Current Aging Science Synthesis and In vitro Evaluation of Thiadiazole Derivatives as AChE, Bu- ChE and LOX Inhibitors
Letters in Drug Design & Discovery Mechanisms of HIV-1 Tat Neurotoxicity via CDK5 Translocation and Hyper-Activation: Role in HIV-Associated Neurocognitive Disorders
Current HIV Research A Urinary Metabolomics Analysis Based on UPLC-MS and Effects of Moxibustion in APP/PS1 Mice
Current Alzheimer Research Astrocyte-Microglia Cooperation in the Expression of a Pro-Inflammatory Phenotype
CNS & Neurological Disorders - Drug Targets Role of Oxidative Stress and Metal Toxicity in the Progression of Alzheimer’s Disease
Current Neuropharmacology Investigation of the Metal Bonding Properties of Some ARA-II Compounds Using Spectrofluorimetric Method
Current Drug Therapy Applications of Chemical Shift Imaging for AD
Current Medical Imaging Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Differential Expression of Ribosomal Genes in Brain and Blood of Alzheimer’s Disease Patients
Current Alzheimer Research Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Wnt/β-Catenin Signaling in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Lithium in Psychiatry-The Benefits and Risks Associated with the Lithium Salts Treatment in Affective Disorders
Current Psychopharmacology A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
Current Drug Metabolism Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy
Current Pharmaceutical Design Chemical Screening and Biological Activities of Extracts from <i>Cistus munbyi</i> Pomel
Current Traditional Medicine The Role of Neuronal Nicotinic Acetylcholine Receptors in Acute and Chronic Neurodegeneration
Current Drug Targets - CNS & Neurological Disorders Ectonucleotidases and Nucleotide/Nucleoside Transporters as Pharmacological Targets for Neurological Disorders
CNS & Neurological Disorders - Drug Targets